Recent Quotes (30 days)

You have no recent quotes
chg | %

Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
+0.83 (1.61%)
Feb. 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.22 - 52.55
52 week 40.51 - 56.42
Open 51.28
Vol / Avg. 790,644.00/510,834.00
Mkt cap 4.10B
P/E 85.67
Div/yield     -
EPS 0.61
Shares 78.48M
Beta 0.67
Inst. own 94%
Feb. 27, 2018
Q4 2017 Integra LifeSciences Holdings Corp Earnings Release - 9:30a.m. EST - Add to calendar
Feb. 27, 2018
Q4 2017 Integra LifeSciences Holdings Corp Earnings Call - 8:30a.m. EST - Add to calendar
Jan. 10, 2018
Integra LifeSciences Holdings Corp at JPMorgan Healthcare Conference - Webcast
Dec. 11, 2017
Integra LifeSciences Holdings Corp Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin 1.13% 7.52%
Operating margin 3.82% 10.81%
EBITD margin - 23.40%
Return on average assets 0.56% 4.16%
Return on average equity 1.40% 9.37%
Employees 3,700 -
CDP Score - -


311 Enterprise Dr
PLAINSBORO, NJ 08536-3344
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Officers and directors

Stuart M. Essig Ph.D. Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Peter J. Arduini President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Lisa Evoli Corporate Vice President, Chief Human Resources Officer
Age: 47
Bio & Compensation  - Reuters
Jeffrey Mosebrook Principal Accounting Officer, Vice President, Corporate Controller
Age: 41
Bio & Compensation  - Reuters
Kenneth Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 63
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 61
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 56
Bio & Compensation  - Reuters
Robert T. Davis Jr. Corporate Vice President, President — Specialty Surgical Solutions
Age: 58
Bio & Compensation  - Reuters
Judith E. O'Grady R.N. Corporate Vice President - Global Regulatory Affairs
Age: 66
Bio & Compensation  - Reuters